MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
1 . A complex comprising an anti-transferrin receptor (TfR) antibody covalently linked to a molecular payload configured for reducing expression or activity of DUX4, wherein the antibody comprises:
a heavy chain variable region (VH) comprising an amino acid sequence at least 95% identical to SEQ ID NO: 77; and/or a light chain variable region (VL) comprising an amino acid sequence at least 95% identical to SEQ ID NO: 78.
2 . The complex of claim 1 , wherein the antibody comprises:
a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 78.
3 . The complex of claim 1 , wherein the antibody is selected from the group consisting of a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, a scFv, a Fv, and a full-length IgG.
4 . The complex of claim 3 , wherein the antibody is a Fab fragment.
5 . The complex of claim 4 , wherein the antibody comprises:
a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 93.
6 . The complex of claim 4 , wherein the antibody comprises:
a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 93.
7 . The complex of claim 1 , wherein the antibody does not specifically bind to the transferrin binding site of the transferrin receptor and/or wherein the antibody does not inhibit binding of transferrin to the transferrin receptor.
8 . The complex of claim 1 , wherein the antibody is cross-reactive with extracellular epitopes of two or more of a human, non-human primate and rodent transferrin receptor.
9 . The complex of claim 1 , wherein the complex is configured to promote transferrin receptor mediated internalization of the molecular payload into a muscle cell.
10 . The complex of claim 1 , wherein the molecular payload is an oligonucleotide.
11 . The complex of claim 10 , wherein the oligonucleotide comprises an antisense strand comprising a region of complementarity to a DUX4 RNA.
12 . The complex of claim 11 , wherein the oligonucleotide comprises an antisense strand comprising a region of complementarity to a non-coding region of the DUX4 RNA.
13 . The complex of claim 11 , wherein the oligonucleotide comprises an antisense strand comprising a region of complementarity to a 5′ or 3′ UTR of the DUX4 RNA.
14 .- 15 . (canceled)
16 . The complex of claim 11 , wherein the oligonucleotide further comprises a sense strand that hybridizes to the antisense strand to form a double stranded siRNA.
17 . The complex of claim 10 , wherein the oligonucleotide comprises at least one modified internucleoside linkage and/or one or more modified nucleosides.
18 .- 19 . (canceled)
20 . The complex claim 10 , wherein the oligonucleotide is a phosphorodiamidate morpholino oligomer.
21 . The complex of claim 1 , wherein the antibody is covalently linked to the molecular payload via a cleavable linker, optionally wherein the cleavable linker comprises a caline-citrulline sequence.
22 . (canceled)
23 . The complex of claim 1 , wherein the antibody is covalently linked to the molecular payload via conjugation to a lysine residue or a cysteine residue of the antibody.
24 .- 25 . (canceled)
26 . A method of reducing DUX4 expression or activity in a cell, the method comprising contacting the cell with the complex of claim 1 in an effective amount for promoting internalization of the molecular payload in the cell, optionally wherein the cell is a muscle cell.
27 . A method of treating a subject having one or more deletions of a D4Z4 repeat in chromosome 4 that is associated with facioscapulohumeral muscular dystrophy, the method comprising administering to the subject an effective amount of the complex of claim 1 .